Risk Factors Update Summary
- Increased risk due to divergent stakeholder views on ESG matters impacting reputation and business.
- Portfolio investments shifted with 78.5% in three industries: Drug Discovery, Software, and Consumer &...
- Changes in investments, e.g., Axsome Therapeutics, Inc. from $162,022 to $135,619.
- Potential impact of LIBOR phase-out on portfolio securities and interest payments.
- Decrease in fair value percentage in various industries, e.g., Drug Discovery from 26% to 23%.
- Shift in investments, e.g., Worldremit Group Limited from $94,020 to $87,876.
- Changes in investments, e.g., Rocket Lab Global Services, LLC from $87,933 to $87,876.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1280784&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.